Paradigm Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-1,200
| Closed | -$55.2K | – | 481 |
|
|
2017
Q2 | $55.2K | Sell |
1,200
-1,200
| -50% | -$55.2K | 0.01% | 516 |
|
|
2017
Q1 | $104K | Sell |
2,400
-10,900
| -82% | -$472K | 0.02% | 521 |
|
|
2016
Q4 | $515K | Sell |
13,300
-400
| -3% | -$15.5K | 0.1% | 207 |
|
|
2016
Q3 | $694K | Buy |
+13,700
| New | +$694K | 0.12% | 174 |
|
|
2016
Q2 | – | Sell |
-21,000
| Closed | -$831K | – | 812 |
|
|
2016
Q1 | $831K | Hold |
21,000
| – | – | 0.15% | 124 |
|
|
2015
Q4 | $1.19M | Sell |
21,000
-45,200
| -68% | -$2.56M | 0.2% | 104 |
|
|
2015
Q3 | $2.63M | Sell |
66,200
-14,500
| -18% | -$577K | 0.35% | 91 |
|
|
2015
Q2 | $3.85M | Hold |
80,700
| – | – | 0.43% | 79 |
|
|
2015
Q1 | $3.2M | Buy |
80,700
+13,400
| +20% | +$532K | 0.36% | 89 |
|
|
2014
Q4 | $1.5M | Sell |
67,300
-8,100
| -11% | -$181K | 0.19% | 156 |
|
|
2014
Q3 | $1.18M | Buy |
+75,400
| New | +$1.18M | 0.17% | 171 |
|